Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer
Top Cited Papers
Open Access
- 22 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (6), 1583-1594
- https://doi.org/10.1158/0008-5472.can-20-3477
Abstract
Ferroptosis is a type of programmed cell death induced by the accumulation of lipid peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated that cancer cells are vulnerable to ferroptosis inducers (FIN). However, the therapeutic potential of FINs in prostate cancer in preclinical settings has not been explored. In this study, we demonstrate that mediators of ferroptosis, solute carrier family 7 member 11, SLC3A2, and glutathione peroxidase, are expressed in treatment-resistant prostate cancer. We further demonstrate that treatment-resistant prostate cancer cells are sensitive to two FINs, erastin and RSL3. Treatment with erastin and RSL3 led to a significant decrease in prostate cancer cell growth and migration in vitro and significantly delayed the tumor growth of treatment-resistant prostate cancer in vivo, with no measurable side effects. Combination of erastin or RSL3 with standard-of-care second-generation antiandrogens for advanced prostate cancer halted prostate cancer cell growth and migration in vitro and tumor growth in vivo. These results demonstrate the potential of erastin or RSL3 independently and in combination with standard-of-care second-generation antiandrogens as novel therapeutic strategies for advanced prostate cancer. These findings reveal that induction of ferroptosis is a new therapeutic strategy for advanced prostate cancer as a monotherapy and in combination with second-generation antiandrogens.Keywords
Other Versions
Funding Information
- Canary Foundation
- NIH NCI (R03CA230819, R37CA240822, R01CA244281)
- PNW Prostate Cancer SPORE (P50CA097186, P01CA163227)
- NIH (CA196387)
- U.S. Army Medical Research Acquisition Activity (W81XWH-19-1-0333)
This publication has 60 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Development of small-molecule probes that selectively kill cells induced to express mutant RASBioorganic & Medicinal Chemistry Letters, 2012
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsCancer Discovery, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- The oxidative stress-inducible cystine/glutamate antiporter, system x c − : cystine supplier and beyondAmino Acids, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer CellsCell Chemical Biology, 2008
- RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channelsNature, 2007